How to Buy aplltd Shares on Fincept?
You can buy Alembic Pharmaceuticals Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Alembic Pharmaceuticals Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Aplltd, including updates on board meetings and corporate actions.
Alembic Pharmaceuticals Limited - https://alembicpharmaceuticals.com
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.
Alembic Pharmaceuticals Limited Share Price Today
909.35
OPEN
939.45
HIGH
905.90
LOW
911.10
CLOSE
83 K
VOLUME
20,428 Cr
Market Cap
171457
Average Volume
Healthcare
Sector
NSI
Exchange
Alembic Pharmaceuticals Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: APLLTD Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Alembic Pharmaceuticals Limited |
APLLTD |
INE901L01018 |
Dividend - Rs 11 Per Share |
15 Jul 2024 |
2 |
N/A |
Alembic Pharmaceuticals Limited |
APLLTD |
INE901L01018 |
Dividend - Rs 8 Per Share |
28 Jul 2023 |
2 |
N/A |
Alembic Pharmaceuticals Limited |
APLLTD |
INE901L01018 |
Interim Dividend - Rs 10 Per Share |
17 Aug 2022 |
2 |
N/A |
Alembic Pharmaceuticals Limited |
APLLTD |
INE901L01018 |
Annual General Meeting/Dividend - Rs 14 Per Share |
19 Jul 2021 |
2 |
N/A |
Alembic Pharmaceuticals Limited |
APLLTD |
INE901L01018 |
Interim Dividend - Rs 7 Per Share Special Dividend - Rs 3 Per Share |
16 Mar 2020 |
2 |
N/A |
NSE: APLLTD Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
APLLTD |
06 Jan 2025, 13:22:39 |
Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
Pharmaceuticals |
APLLTD |
01 Jan 2025, 15:58:24 |
Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent |
Pharmaceuticals |
APLLTD |
01 Jan 2025, 15:54:01 |
Change in Management |
Pharmaceuticals |
APLLTD |
01 Jan 2025, 15:41:39 |
Updates |
Pharmaceuticals |
APLLTD |
27 Dec 2024, 17:04:53 |
Trading Window-XBRL |
Pharmaceuticals |
NSE: APLLTD Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Alembic Pharmaceuticals Limited |
APLLTD |
17 Oct 2024, 11:44:00 |
17 Oct 2024, 11:44:00 |
|
Alembic Pharmaceuticals Limited |
APLLTD |
07 Nov 2024, 19:29:00 |
07 Nov 2024, 19:29:00 |
|
Alembic Pharmaceuticals Limited |
APLLTD |
12 Jul 2024, 19:33:00 |
12 Jul 2024, 19:33:00 |
|
Alembic Pharmaceuticals Limited |
APLLTD |
18 Apr 2024, 19:53:00 |
18 Apr 2024, 20:15:00 |
|
Alembic Pharmaceuticals Limited |
APLLTD |
08 Jan 2024, 19:45:00 |
08 Jan 2024, 20:15:00 |
NSE: APLLTD Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson Related To Promoters,Executive Director-CEO |
04 Dec 1946 |
16 Jun 2010 |
00242549 |
Chirayu Ramanbhai Amin |
Active |
Executive Director-MD |
05 Oct 1975 |
31 Mar 2011 |
00245099 |
Pranav Chirayu Amin |
Active |
Executive Director-MD |
01 May 1978 |
02 May 2013 |
00245523 |
Shaunak Chirayu Amin |
Active |
Independent Director |
05 Dec 1956 |
10 Feb 2022 |
00492930 |
Ashok Kumar Barat |
Active |
Independent Director |
09 Sep 1965 |
04 Feb 2015 |
00028037 |
Archana N Hingorani |
Active |
NSE: APLLTD Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
ALEMBIC PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 07-Nov-2024 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2024 and Other business. |
APLLTD |
N/A |
INE901L01018 |
Alembic Pharmaceuticals Limited |
18 Oct 2024, 12:05:00 |
Financial Results |
APLLTD |
N/A |
INE901L01018 |
Alembic Pharmaceuticals Limited |
25 Jul 2024, 16:48:40 |
ALEMBIC PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 08-Aug-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended June 2024 and Other business. |
APLLTD |
N/A |
INE901L01018 |
Alembic Pharmaceuticals Limited |
25 Jul 2024, 16:51:53 |
ALEMBIC PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 09-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Dividend. |
APLLTD |
N/A |
INE901L01018 |
Alembic Pharmaceuticals Limited |
18 Apr 2024, 13:50:03 |
ALEMBIC PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 05-Feb-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2023 and Other business. |
APLLTD |
N/A |
INE901L01018 |
Alembic Pharmaceuticals Limited |
18 Jan 2024, 17:25:03 |
NSE: APLLTD Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results |
APLLTD |
- |
INE901L01018 |
Alembic Pharmaceuticals Limited |
18 Oct 2024, 00:00:00 |
To consider and approve the financial results for the quarter and half year ended September 30, 2024 |
Financial Results |
APLLTD |
- |
INE901L01018 |
Alembic Pharmaceuticals Limited |
25 Jul 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 |
Financial Results/Dividend |
APLLTD |
- |
INE901L01018 |
Alembic Pharmaceuticals Limited |
18 Apr 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024 and dividend for the financial year 2023-24 |
Financial Results/Other business matters |
APLLTD |
- |
INE901L01018 |
Alembic Pharmaceuticals Limited |
18 Jan 2024, 00:00:00 |
To consider and approve the financial results for the period ended December 31, 2023 and other business matters |
Financial Results/Other business matters |
APLLTD |
- |
INE901L01018 |
Alembic Pharmaceuticals Limited |
16 Oct 2023, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2023 and other business matters |
NSE: APLLTD Balance Sheet Data In (Cr)
| date | period_type | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Other Non Current Liabilities | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Debt And Capital Lease Obligation | Current Capital Lease Obligation | Current Debt | Current Provisions | Payables | Other Payable | Dividends Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Non Current Deferred Taxes Assets | Investmentin Financial Assets | Available For Sale Securities | Financial Assets Designatedas Fair Value Through Profitor Loss | Long Term Equity Investment | Investmentsin Joint Venturesat Cost | Investments In Other Ventures Under Equity Method | Investmentsin Associatesat Cost | Investmentsin Subsidiariesat Cost | Goodwill And Other Intangible Assets | Other Intangible Assets | Goodwill | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Hedging Assets Current | Restricted Cash | Prepaid Assets | Inventory | Other Inventories | Finished Goods | Work In Process | Raw Materials | Other Receivables | Taxes Receivable | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 196,563,124.00 | 196,563,124.00 | 8,729,000,000.00 | 10,663,500,000.00 | 48,880,600,000.00 | 58,830,100,000.00 | 15,905,700,000.00 | 48,880,600,000.00 | 714,000,000.00 | 48,880,600,000.00 | 48,880,600,000.00 | 48,876,400,000.00 | -4,200,000.00 | 48,880,600,000.00 | 48,487,500,000.00 | 0.00 | 0.00 | 393,100,000.00 | 393,100,000.00 | 23,426,100,000.00 | 1,707,900,000.00 | 0.00 | 0.00 | 534,300,000.00 | 534,300,000.00 | 0.00 | 1,173,600,000.00 | 21,718,200,000.00 | 694,400,000.00 | 10,129,200,000.00 | 179,700,000.00 | 9,949,500,000.00 | 620,800,000.00 | 8,892,300,000.00 | 0.00 | 0.00 | 0.00 | 8,892,300,000.00 | 72,302,500,000.00 | 34,678,400,000.00 | 419,000,000.00 | 0.00 | 1,993,200,000.00 | 760,900,000.00 | 760,900,000.00 | 0.00 | 256,700,000.00 | 0.00 | 256,700,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31,248,600,000.00 | 0.00 | 31,248,600,000.00 | 6,616,300,000.00 | 24,632,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37,623,900,000.00 | 3,051,100,000.00 | 0.00 | 0.00 | 0.00 | 20,125,200,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 278,100,000.00 | 12,676,800,000.00 | 0.00 | 0.00 | 1,492,700,000.00 | 272,200,000.00 | 1,220,500,000.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 196,563,124.00 | 196,563,124.00 | 3,102,400,000.00 | 5,131,600,000.00 | 48,181,900,000.00 | 52,486,400,000.00 | 16,235,600,000.00 | 48,181,900,000.00 | 827,100,000.00 | 48,181,900,000.00 | 48,181,900,000.00 | 48,181,900,000.00 | 0.00 | 48,181,900,000.00 | 47,788,900,000.00 | 40,270,100,000.00 | 7,483,900,000.00 | 393,100,000.00 | 393,100,000.00 | 16,273,900,000.00 | 1,723,900,000.00 | 0.00 | 0.00 | 628,800,000.00 | 628,800,000.00 | 0.00 | 1,095,100,000.00 | 14,550,000,000.00 | 599,500,000.00 | 4,502,800,000.00 | 198,300,000.00 | 4,304,500,000.00 | 652,500,000.00 | 9,122,600,000.00 | 1,706,700,000.00 | 59,500,000.00 | 0.00 | 7,356,400,000.00 | 64,455,800,000.00 | 33,670,200,000.00 | 333,000,000.00 | 333,000,000.00 | 1,696,400,000.00 | 681,700,000.00 | 498,500,000.00 | 183,200,000.00 | 248,600,000.00 | 5,200,000.00 | 0.00 | 238,900,000.00 | 4,500,000.00 | 0.00 | 0.00 | 0.00 | 30,710,500,000.00 | -13,285,000,000.00 | 43,995,500,000.00 | 5,243,600,000.00 | 4,372,200,000.00 | 24,114,600,000.00 | 8,904,900,000.00 | 1,360,200,000.00 | 0.00 | 30,785,600,000.00 | 2,218,100,000.00 | 30,900,000.00 | 63,600,000.00 | 2,327,700,000.00 | 16,435,400,000.00 | 935,700,000.00 | 10,521,100,000.00 | 695,200,000.00 | 4,283,400,000.00 | 67,200,000.00 | 410,300,000.00 | 10,248,400,000.00 | -355,900,000.00 | 10,604,300,000.00 | 1,202,100,000.00 | 271,300,000.00 | 1,202,100,000.00 | 1,202,100,000.00 |
| 2024-03-31T00:00:00 | annual | 196,563,124.00 | 196,563,124.00 | 3,102,400,000.00 | 5,131,600,000.00 | 48,181,900,000.00 | 52,486,400,000.00 | 16,235,600,000.00 | 48,181,900,000.00 | 827,100,000.00 | 48,181,900,000.00 | 48,181,900,000.00 | 48,181,900,000.00 | 0.00 | 48,181,900,000.00 | 47,788,900,000.00 | 40,270,100,000.00 | 7,483,900,000.00 | 393,100,000.00 | 393,100,000.00 | 16,273,900,000.00 | 1,723,900,000.00 | 0.00 | 0.00 | 628,800,000.00 | 628,800,000.00 | 0.00 | 1,095,100,000.00 | 14,550,000,000.00 | 599,500,000.00 | 4,502,800,000.00 | 198,300,000.00 | 4,304,500,000.00 | 652,500,000.00 | 9,122,600,000.00 | 1,706,700,000.00 | 59,500,000.00 | 0.00 | 7,356,400,000.00 | 64,455,800,000.00 | 33,670,200,000.00 | 333,000,000.00 | 333,000,000.00 | 1,696,400,000.00 | 681,700,000.00 | 498,500,000.00 | 183,200,000.00 | 248,600,000.00 | 5,200,000.00 | 0.00 | 238,900,000.00 | 4,500,000.00 | 0.00 | 0.00 | 0.00 | 30,710,500,000.00 | -13,285,000,000.00 | 43,995,500,000.00 | 5,243,600,000.00 | 4,372,200,000.00 | 24,114,600,000.00 | 8,904,900,000.00 | 1,360,200,000.00 | 0.00 | 30,785,600,000.00 | 2,218,100,000.00 | 30,900,000.00 | 63,600,000.00 | 2,327,700,000.00 | 16,435,400,000.00 | 935,700,000.00 | 10,521,100,000.00 | 695,200,000.00 | 4,283,400,000.00 | 67,200,000.00 | 410,300,000.00 | 10,248,400,000.00 | -355,900,000.00 | 10,604,300,000.00 | 1,202,100,000.00 | 271,300,000.00 | 1,202,100,000.00 | 1,202,100,000.00 |
| 2023-09-30T00:00:00 | quarterly | 196,563,124.00 | 196,563,124.00 | 6,430,800,000.00 | 8,687,700,000.00 | 44,700,100,000.00 | 52,543,900,000.00 | 13,242,200,000.00 | 44,700,100,000.00 | 843,900,000.00 | 44,700,100,000.00 | 44,700,100,000.00 | 44,700,100,000.00 | 0.00 | 44,700,100,000.00 | 44,307,000,000.00 | 0.00 | 0.00 | 393,100,000.00 | 393,100,000.00 | 19,852,600,000.00 | 1,753,500,000.00 | 100,000.00 | 0.00 | 674,100,000.00 | 674,100,000.00 | 0.00 | 1,079,300,000.00 | 18,099,100,000.00 | 768,000,000.00 | 8,013,600,000.00 | 169,800,000.00 | 7,843,800,000.00 | 655,400,000.00 | 7,619,500,000.00 | 0.00 | 0.00 | 0.00 | 7,619,500,000.00 | 64,552,700,000.00 | 33,211,300,000.00 | 188,000,000.00 | 0.00 | 1,237,000,000.00 | 730,400,000.00 | 730,400,000.00 | 0.00 | 247,700,000.00 | 0.00 | 247,700,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30,808,200,000.00 | 0.00 | 30,808,200,000.00 | 4,781,200,000.00 | 26,027,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31,341,300,000.00 | 2,888,700,000.00 | 0.00 | 0.00 | 0.00 | 15,392,400,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 724,300,000.00 | 10,750,700,000.00 | 0.00 | 0.00 | 1,585,200,000.00 | 172,200,000.00 | 1,413,000,000.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 196,563,124.00 | 196,563,124.00 | 5,603,800,000.00 | 7,220,100,000.00 | 43,704,600,000.00 | 50,063,200,000.00 | 12,731,000,000.00 | 43,704,600,000.00 | 861,500,000.00 | 43,704,600,000.00 | 43,704,600,000.00 | 43,704,600,000.00 | 0.00 | 43,704,600,000.00 | 43,311,600,000.00 | 35,684,400,000.00 | 7,483,900,000.00 | 393,100,000.00 | 393,100,000.00 | 18,123,700,000.00 | 1,754,500,000.00 | 200,000.00 | 0.00 | 692,300,000.00 | 692,300,000.00 | 0.00 | 1,062,000,000.00 | 16,369,200,000.00 | 855,400,000.00 | 6,527,800,000.00 | 169,200,000.00 | 6,358,600,000.00 | 700,600,000.00 | 8,439,700,000.00 | 1,577,700,000.00 | 63,900,000.00 | 0.00 | 6,798,100,000.00 | 61,828,300,000.00 | 32,728,100,000.00 | 537,400,000.00 | 537,400,000.00 | 1,230,100,000.00 | 707,500,000.00 | 636,100,000.00 | 71,400,000.00 | 255,800,000.00 | 5,100,000.00 | 0.00 | 246,200,000.00 | 4,500,000.00 | 0.00 | 0.00 | 0.00 | 29,997,300,000.00 | -10,690,500,000.00 | 40,687,800,000.00 | 6,012,800,000.00 | 4,342,300,000.00 | 20,618,300,000.00 | 8,350,000,000.00 | 1,364,400,000.00 | 0.00 | 29,100,200,000.00 | 2,135,200,000.00 | 0.00 | 67,900,000.00 | 2,233,700,000.00 | 14,752,700,000.00 | 689,300,000.00 | 9,037,200,000.00 | 750,700,000.00 | 4,275,500,000.00 | 0.00 | 827,100,000.00 | 10,464,000,000.00 | -284,200,000.00 | 10,748,200,000.00 | 754,800,000.00 | 166,400,000.00 | 754,800,000.00 | 754,800,000.00 |
| 2023-03-31T00:00:00 | annual | 196,563,124.00 | 196,563,124.00 | 5,603,800,000.00 | 7,220,100,000.00 | 43,704,600,000.00 | 50,063,200,000.00 | 12,731,000,000.00 | 43,704,600,000.00 | 861,500,000.00 | 43,704,600,000.00 | 43,704,600,000.00 | 43,704,600,000.00 | 0.00 | 43,704,600,000.00 | 43,311,600,000.00 | 35,684,400,000.00 | 7,483,900,000.00 | 393,100,000.00 | 393,100,000.00 | 18,123,700,000.00 | 1,754,500,000.00 | 200,000.00 | 0.00 | 692,300,000.00 | 692,300,000.00 | 0.00 | 1,062,000,000.00 | 16,369,200,000.00 | 855,400,000.00 | 6,527,800,000.00 | 169,200,000.00 | 6,358,600,000.00 | 700,600,000.00 | 8,439,700,000.00 | 1,577,700,000.00 | 63,900,000.00 | 0.00 | 6,798,100,000.00 | 61,828,300,000.00 | 32,728,100,000.00 | 537,400,000.00 | 537,400,000.00 | 1,230,100,000.00 | 707,500,000.00 | 636,100,000.00 | 71,400,000.00 | 255,800,000.00 | 5,100,000.00 | 0.00 | 246,200,000.00 | 4,500,000.00 | 0.00 | 0.00 | 0.00 | 29,997,300,000.00 | -10,690,500,000.00 | 40,687,800,000.00 | 6,012,800,000.00 | 4,342,300,000.00 | 20,618,300,000.00 | 8,350,000,000.00 | 1,364,400,000.00 | 0.00 | 29,100,200,000.00 | 2,135,200,000.00 | 0.00 | 67,900,000.00 | 2,233,700,000.00 | 14,752,700,000.00 | 689,300,000.00 | 9,037,200,000.00 | 750,700,000.00 | 4,275,500,000.00 | 0.00 | 827,100,000.00 | 10,464,000,000.00 | -284,200,000.00 | 10,748,200,000.00 | 754,800,000.00 | 166,400,000.00 | 754,800,000.00 | 754,800,000.00 |
| 2022-03-31T00:00:00 | annual | 196,563,124.00 | 196,563,124.00 | 5,689,000,000.00 | 7,171,100,000.00 | 50,827,300,000.00 | 58,675,400,000.00 | 11,442,600,000.00 | 50,827,300,000.00 | 871,200,000.00 | 52,375,500,000.00 | 52,375,500,000.00 | 52,375,500,000.00 | 0.00 | 52,375,500,000.00 | 51,982,400,000.00 | 25,543,900,000.00 | 7,983,900,000.00 | 393,100,000.00 | 393,100,000.00 | 18,844,800,000.00 | 1,679,500,000.00 | -100,000.00 | 0.00 | 721,400,000.00 | 721,400,000.00 | 0.00 | 958,200,000.00 | 17,165,300,000.00 | -100,000.00 | 6,449,700,000.00 | 149,800,000.00 | 6,299,900,000.00 | 636,400,000.00 | 9,263,500,000.00 | 2,135,500,000.00 | 64,100,000.00 | 0.00 | 7,063,900,000.00 | 71,220,300,000.00 | 42,612,400,000.00 | -200,000.00 | 348,800,000.00 | 58,800,000.00 | 632,400,000.00 | 632,400,000.00 | 0.00 | 551,700,000.00 | 4,800,000.00 | 0.00 | 542,400,000.00 | 4,500,000.00 | 1,548,200,000.00 | 1,548,200,000.00 | 0.00 | 39,472,700,000.00 | -8,594,900,000.00 | 48,067,600,000.00 | 22,057,900,000.00 | 4,045,200,000.00 | 14,245,400,000.00 | 6,440,600,000.00 | 1,278,500,000.00 | 0.00 | 28,607,900,000.00 | 200,000.00 | 145,700,000.00 | 83,400,000.00 | 3,348,600,000.00 | 16,097,000,000.00 | 610,700,000.00 | 9,687,500,000.00 | 886,800,000.00 | 4,912,000,000.00 | 0.00 | 250,800,000.00 | 8,071,300,000.00 | -333,300,000.00 | 8,404,600,000.00 | 610,900,000.00 | 316,200,000.00 | 610,900,000.00 | 610,900,000.00 |
| 2021-03-31T00:00:00 | annual | 196,563,124.00 | 196,563,124.00 | 4,017,300,000.00 | 5,836,100,000.00 | 47,431,500,000.00 | 55,667,500,000.00 | 13,711,600,000.00 | 47,431,500,000.00 | 838,200,000.00 | 50,669,600,000.00 | 52,668,500,000.00 | 50,669,600,000.00 | -606,400,000.00 | 50,669,600,000.00 | 0.00 | 23,849,400,000.00 | 8,733,900,000.00 | 393,100,000.00 | 393,100,000.00 | 16,420,200,000.00 | 3,611,800,000.00 | 200,000.00 | 42,100,000.00 | 2,714,300,000.00 | 715,400,000.00 | 1,998,900,000.00 | 855,200,000.00 | 12,808,400,000.00 | 200,000.00 | 3,121,800,000.00 | 122,800,000.00 | 2,999,000,000.00 | 519,900,000.00 | 8,812,700,000.00 | 2,044,500,000.00 | 59,000,000.00 | 21,500,000.00 | 6,687,700,000.00 | 67,089,800,000.00 | 40,569,700,000.00 | -200,000.00 | 367,000,000.00 | 0.00 | 0.00 | 4,500,000.00 | 4,500,000.00 | 493,200,000.00 | 4,600,000.00 | 488,600,000.00 | 484,100,000.00 | 4,500,000.00 | 3,238,100,000.00 | 3,238,100,000.00 | 0.00 | 36,471,600,000.00 | -6,628,400,000.00 | 43,100,000,000.00 | 19,442,800,000.00 | 3,511,300,000.00 | 12,887,600,000.00 | 6,120,400,000.00 | 1,137,900,000.00 | 0.00 | 26,520,000,000.00 | -100,000.00 | 429,400,000.00 | 77,800,000.00 | 4,649,300,000.00 | 14,861,500,000.00 | 587,000,000.00 | 9,474,600,000.00 | 668,000,000.00 | 4,131,900,000.00 | 0.00 | 166,000,000.00 | 3,485,800,000.00 | -251,000,000.00 | 3,736,800,000.00 | 2,850,300,000.00 | 1,869,700,000.00 | 980,600,000.00 | 980,600,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -289,600,000.00 | 0.00 | 100,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100,000.00 | 121,900,000.00 | 0.00 | 0.00 | 8,869,900,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 171,700,000.00 | 0.00 | 0.00 | 0.00 | 2,990,200,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: APLLTD Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repayment Of Debt | Issuance Of Debt | Issuance Of Capital Stock | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Effect Of Exchange Rate Changes | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Common Stock Issuance | Common Stock Issuance | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Net Long Term Debt Issuance | Long Term Debt Payments | Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Interest Received Cfi | Dividends Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net Business Purchase And Sale | Purchase Of Business | Net Intangibles Purchase And Sale | Purchase Of Intangibles | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Capital Expenditure Reported | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Other Current Assets | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Provisionand Write Offof Assets | Depreciation And Amortization | Depreciation | Pension And Employee Benefit Expense | Gain Loss On Investment Securities | Net Foreign Currency Exchange Gain Loss | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 4,757,300,000.00 | 0.00 | 0.00 | 0.00 | -3,274,700,000.00 | 1,202,100,000.00 | 100,000.00 | 754,800,000.00 | 0.00 | 447,200,000.00 | -4,378,700,000.00 | -200,000.00 | -493,700,000.00 | -1,572,500,000.00 | 0.00 | 0.00 | 0.00 | -2,054,100,000.00 | -2,054,100,000.00 | 0.00 | 0.00 | 0.00 | -3,206,100,000.00 | -100,000.00 | 19,900,000.00 | 16,400,000.00 | -83,200,000.00 | 0.00 | -83,200,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3,159,100,000.00 | 115,600,000.00 | -3,274,700,000.00 | 0.00 | 8,032,000,000.00 | -198,500,000.00 | -956,500,000.00 | -15,400,000.00 | -175,800,000.00 | 560,400,000.00 | -1,682,800,000.00 | 390,500,000.00 | 541,000,000.00 | 53,600,000.00 | 2,726,700,000.00 | 2,726,700,000.00 | 0.00 | -44,000,000.00 | -401,500,000.00 | -17,000,000.00 | 6,318,300,000.00 |
| 2023-03-31T00:00:00 | annual | 2,805,400,000.00 | -2,000,000,000.00 | 0.00 | 0.00 | -4,434,100,000.00 | 754,800,000.00 | -100,000.00 | 610,900,000.00 | 0.00 | 144,000,000.00 | -2,619,600,000.00 | 15,300,000.00 | -497,000,000.00 | -1,965,600,000.00 | 0.00 | 0.00 | 0.00 | 58,700,000.00 | 2,058,700,000.00 | -2,000,000,000.00 | -2,000,000,000.00 | 0.00 | -4,475,900,000.00 | 100,000.00 | 3,300,000.00 | 6,100,000.00 | -70,000,000.00 | 0.00 | -70,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4,415,400,000.00 | 18,700,000.00 | -4,434,100,000.00 | 0.00 | 7,239,500,000.00 | -607,000,000.00 | -575,600,000.00 | -841,800,000.00 | 1,271,400,000.00 | -281,700,000.00 | 1,344,400,000.00 | -2,228,800,000.00 | 1,482,800,000.00 | 0.00 | 2,754,300,000.00 | 2,754,300,000.00 | 0.00 | -7,500,000.00 | 290,600,000.00 | 47,000,000.00 | 3,545,900,000.00 |
| 2022-03-31T00:00:00 | annual | 1,267,100,000.00 | -3,000,000,000.00 | 0.00 | 0.00 | -4,256,400,000.00 | 610,900,000.00 | 0.00 | 980,600,000.00 | 0.00 | -369,700,000.00 | -2,173,500,000.00 | -500,000.00 | -519,200,000.00 | -2,751,900,000.00 | 0.00 | 0.00 | 0.00 | 1,299,800,000.00 | 4,299,800,000.00 | -3,000,000,000.00 | -3,000,000,000.00 | 0.00 | -3,719,700,000.00 | 13,800,000.00 | 17,300,000.00 | 28,800,000.00 | 476,800,000.00 | 1,869,700,000.00 | -1,392,900,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4,256,400,000.00 | 0.00 | -4,256,400,000.00 | 0.00 | 5,523,500,000.00 | -1,234,300,000.00 | -3,673,400,000.00 | 432,200,000.00 | 1,281,900,000.00 | 366,700,000.00 | -1,235,500,000.00 | -4,696,200,000.00 | 961,300,000.00 | 73,000,000.00 | 2,867,800,000.00 | 2,867,800,000.00 | 0.00 | -34,200,000.00 | 364,500,000.00 | 0.00 | 6,253,900,000.00 |
| 2021-03-31T00:00:00 | annual | 8,038,700,000.00 | -3,792,700,000.00 | 0.00 | 7,340,800,000.00 | -6,595,100,000.00 | 980,600,000.00 | 100,000.00 | 718,400,000.00 | -9,300,000.00 | 271,400,000.00 | -5,974,300,000.00 | -1,000,000.00 | -729,400,000.00 | 0.00 | 0.00 | 7,340,800,000.00 | 7,340,800,000.00 | -12,397,500,000.00 | -8,604,800,000.00 | -3,792,700,000.00 | -3,792,700,000.00 | 0.00 | -8,388,100,000.00 | 2,600,000.00 | 15,800,000.00 | 49,600,000.00 | -1,861,000,000.00 | 0.00 | -1,861,000,000.00 | -4,600,000.00 | -4,600,000.00 | 0.00 | 0.00 | -6,595,100,000.00 | 0.00 | -6,595,100,000.00 | 0.00 | 14,633,800,000.00 | -2,454,400,000.00 | 2,383,000,000.00 | 1,033,500,000.00 | -1,461,900,000.00 | 452,700,000.00 | -2,986,200,000.00 | 5,109,300,000.00 | 144,400,000.00 | 60,600,000.00 | 1,834,700,000.00 | 1,834,700,000.00 | -12,500,000.00 | -76,800,000.00 | -938,800,000.00 | 0.00 | 13,680,800,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 3,780,200,000.00 | 0.00 | 0.00 | 0.00 | 100,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3,259,700,000.00 | -3,259,700,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,780,200,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -622,500,000.00 | -622,500,000.00 | 0.00 | 0.00 | 0.00 | -6,726,500,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -114,200,000.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: APLLTD Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Minority Interests | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Write Off | Net Non Operating Interest Income Expense | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Depreciation Income Statement | Research And Development | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 0.13 | 0.00 | 955.48 | 5.21 | 5.21 | 615.82 | 272.67 | 2,000.70 | 960.69 | 688.02 | -54.10 | 56.19 | 2.09 | 610.74 | 615.82 | 5,448.57 | 0.00 | 19.66 | 19.66 | 0.00 | 0.00 | 615.82 | 615.82 | 0.00 | 615.82 | 0.00 | 615.82 | 615.83 | 16.00 | 631.83 | 0.45 | 0.82 | -3.68 | 2.86 | -54.10 | 56.19 | 2.09 | 663.54 | 3,447.87 | 575.59 | 272.67 | 272.67 | 20.98 | 1,248.85 | 996.88 | 251.97 | 0.00 | 4,111.41 | 2,000.70 | 6,112.11 | 6,112.11 |
| 2023-03-31T00:00:00 | annual | -0.32 | 0.00 | 689.11 | -8.92 | -8.92 | 341.99 | 275.43 | 2,023.16 | 680.19 | 404.76 | -49.84 | 50.17 | 0.33 | 350.59 | 341.99 | 5,055.69 | 0.00 | 19.66 | 19.66 | 0.00 | 0.00 | 341.99 | 341.99 | 0.00 | 341.99 | 0.00 | 341.99 | 341.98 | 12.61 | 354.59 | 0.27 | -9.67 | 3.32 | 6.35 | -49.84 | 50.17 | 0.33 | 444.08 | 3,032.53 | 518.40 | 275.43 | 275.43 | 29.07 | 1,193.35 | 952.30 | 241.05 | 0.00 | 3,476.61 | 2,023.16 | 5,499.77 | 5,499.77 |
| 2022-03-31T00:00:00 | annual | -0.23 | 0.00 | 931.26 | -1.36 | -1.36 | 520.94 | 286.78 | 1,723.19 | 929.90 | 643.12 | -16.00 | 17.73 | 1.73 | 522.07 | 520.94 | 4,638.81 | 0.00 | 19.66 | 19.66 | 0.00 | 0.00 | 520.94 | 520.94 | 0.00 | 520.94 | 24.75 | 520.94 | 520.93 | 104.46 | 625.39 | 0.13 | -4.23 | -1.01 | 5.24 | -16.00 | 17.73 | 1.73 | 592.98 | 2,915.62 | 417.88 | 286.78 | 286.78 | 50.59 | 1,101.36 | 890.38 | 210.98 | 0.00 | 3,508.60 | 1,723.19 | 5,231.79 | 5,231.79 |
| 2021-03-31T00:00:00 | annual | 1.52 | 0.00 | 1,559.34 | 8.23 | 8.23 | 1,146.50 | 183.47 | 1,521.27 | 1,567.57 | 1,384.10 | -14.44 | 16.02 | 1.58 | 1,139.79 | 1,146.50 | 3,979.38 | 1.62 | 19.37 | 19.37 | 0.00 | 0.00 | 1,146.50 | 1,146.50 | 0.00 | 1,146.50 | 31.61 | 1,146.50 | 1,146.50 | 253.32 | 1,368.08 | 0.20 | 1.95 | -1.95 | 0.00 | -14.44 | 16.02 | 1.58 | 1,296.84 | 2,458.11 | 410.10 | 183.47 | 183.47 | 25.38 | 904.91 | 687.41 | 217.50 | 1.62 | 3,754.95 | 1,521.27 | 5,276.22 | 5,276.22 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.29 | 0.00 | 0.00 | 0.00 | 0.00 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
6/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
32.92
P/E
31.568956
P/B
4.186962
Dividend Yield
1.04%
Market Cap
20,427.81 Cr.
Face Value
248.211
Book Value
248.211
ROE
10.17%
EBITDA Growth
983.24 Cr.
Debt/Equity
21.817
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of aplltd?
The market capitalization of Alembic Pharmaceuticals Limited is ₹20,428 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Alembic Pharmaceuticals Limited?
The PE and PB ratios of Alembic Pharmaceuticals Limited are Not Available and 4.186962 respectively as of 05 Feb 2025.
What is the 52 Week High of Alembic Pharmaceuticals Limited?
The 52-week high of Alembic Pharmaceuticals Limited is ₹1303.9 as of 05 Feb 2025.
What is the 52 Week Low of Alembic Pharmaceuticals Limited?
The 52-week low of Alembic Pharmaceuticals Limited is ₹746.5 as of 05 Feb 2025.
What are the earnings per share (EPS) for Alembic Pharmaceuticals Limited?
The Earnings Per Share (EPS) of Alembic Pharmaceuticals Limited is ₹32.92 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Alembic Pharmaceuticals Limited?
The Return on Equity (ROE) of Alembic Pharmaceuticals Limited is 10.17% as per the most recent financial year data. Explore more on Fincept.